Clinical Trial Update: Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating brentuximab vedotin in refractory/relapsed Hodgkin lymphoma treated with ICE; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Hodgkin Disease | Phase 1, Phase 2 | Status: COMPLETED